Bio-Techne Corporation
TECH
Clasificación en acciones
#1875
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures,... Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Precio por acción
$72.55
Última sincronización: 2026-10-16
Capitalización bursátil
$11.38B
Cambio (1 día)
0.03%
Cambio (1 año)
17.27%
País
US
Comercio Bio-Techne Corporation (TECH)
Categoría
Healthcare
Ganancias de Bio-Techne Corporation (TECH)
Ganancias en Jun 2026 TTM: $240.68M
Secondo gli ultimi rapporti finanziari di Bio-Techne Corporation, gli utili attuali della società sono $240.68M. Nel 2024, la società ha registrato un utile di $185.69M, una disminución en comparación con agli utili del 2023, che erano di $338.66M. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Bio-Techne Corporation desde 2000 hasta 2026
Ganancias al final de cada año
| Año | Ganancias | Cambiar |
|---|---|---|
| 2026 (TTM) | $240.68M | 144.44% |
| 2025 | $98.46M | -46.97% |
| 2024 | $185.69M | -45.17% |
| 2023 | $338.66M | 12.37% |
| 2022 | $301.39M | 103.40% |
| 2021 | $148.18M | -46.41% |
| 2020 | $276.48M | 146.82% |
| 2019 | $112.02M | -11.07% |
| 2018 | $125.95M | 11.30% |
| 2017 | $113.16M | -23.27% |
| 2016 | $147.48M | -4.33% |
| 2015 | $154.16M | -4.48% |
| 2014 | $161.39M | 0.45% |
| 2013 | $160.66M | -0.95% |
| 2012 | $162.20M | -1.69% |
| 2011 | $164.98M | 5.46% |
| 2010 | $156.45M | 0.70% |
| 2009 | $155.36M | 1.00% |
| 2008 | $153.83M | 19.31% |
| 2007 | $128.93M | 15.98% |
| 2006 | $111.16M | 11.29% |
| 2005 | $99.89M | 21.02% |
| 2004 | $82.54M | 18.67% |
| 2003 | $69.56M | 84.32% |
| 2002 | $37.74M | -21.07% |
| 2001 | $47.81M | 21.30% |
| 2000 | $39.41M | 0.00% |
Ganancias de empresas similares o competidoras
| Empresa | Ganancias | Diferencia de ganancias | País |
|---|---|---|---|
| $5.27B | 2,091.67% |
US
|
|
| $-3.09B | -1,382.62% |
US
|
|
| $-4.02B | -1,768.69% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | 710.47% |
NL
|
